Home>Topics>Companies>Eli Lilly

Eli Lilly LLY

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Ad Comm says TRT drug makers should conduct new trials to assess heart risk

      Headlines

      Thu, 18 Sep 2014

      almost doubled from 2010 to 2013. About 20% of TRT patients do not have laboratory evidence that they need the therapy. Eli Lilly (NYSE: LLY ) says that current evidence does not support a causal link between TRT and cardiovascular events. Based

    2. Cautionary Stance Points to More Stringent Product Labeling at Axiron: Reducing Fair Value Estimate

      Commentary

      Wed, 17 Sep 2014

      studies are now underway, including one sponsored by Eli Lilly , evaluating the impact of testosterone across a number ..... shift of the USD 50 million milestone payment under the Eli Lilly agreement, from fiscal 2015 to fiscal 2016. The shares

    3. New Analyst Report for ACR

      Stock Reports

      Wed, 17 Sep 2014

      understanding of Acrux's potential, Eli Lilly may move to acquire the company ..... Nonetheless, the Axiron deal with Eli Lilly in 2010 was a major transaction for ..... out-licensed its lead product, Axiron, to Eli Lilly which is now the key driver of revenues

    4. Update: AstraZeneca Announces Licensing Agreement

      Headlines

      Tue, 16 Sep 2014

      exacerbate top line pressure, prompting concern about its long-term prospects. But with the licensing agreement with Eli Lilly (NYSE: LLY ) to develop Astra's BACE inhibitor AZD3293 for Alzheimer's disease, there is more evidence to support

    5. Eli Lilly Will Soon Emerge As A Star

      Headlines

      Tue, 16 Sep 2014

      By Balanced Investing : Eli Lilly and Co. (NYSE: LLY ), a drug ..... it still has a lot going for it. Eli Lilly has big opportunities available in ..... Big Markets, Big Opportunities Eli Lilly has a blockbuster drug in the diabetes

    6. AstraZeneca, Eli Lilly partner up on Alzheimer's drug

      Headlines

      Tue, 16 Sep 2014

      to find a partner for its experimental Alzheimer's drug, AstraZeneca (NYSE: AZN ) has now agreed to team up with Eli Lilly (NYSE: LLY ). Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M, depending on the progress

    7. AstraZeneca to partner with Eli Lilly on Alzheimer's drug

      Headlines

      Tue, 16 Sep 2014

      LONDON, Sept 16 (Reuters) - AstraZeneca has struck a partnership deal worth up to $500 million with Eli Lilly for the British group's experimental Alzheimer's drug, which is set to enter late-stage...

    8. BRIEF-AstraZeneca to develop Alzheimer's drug with Eli Lilly

      Headlines

      Tue, 16 Sep 2014

      * Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments

    9. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

      Headlines

      Tue, 16 Sep 2014

      RHHBY 3 Wide 36.7 1.05 3 Low 5 - Eli Lilly LLY 3 Wide 65.27 1.11 3 Medium ..... Pfizer, Sanofi, Roche, and Eli Lilly LLY--accounting for four of the ..... shares of Vodafone VOD, Sanofi, and Eli Lilly , none of which made out list of

    10. New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin

      Headlines

      Sun, 14 Sep 2014

      Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE: LLY ) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type

    « Prev12345Next »
    Content Partners